在FDA因参与者脑肿瘤停止试验后, RHX-111基因疗法安全面临误导投资者的诉讼。 REGENXBIO faces lawsuit for misleading investors about RGX-111 gene therapy safety, after FDA halted trials due to a participant’s brain tumor.

已经对REGEN XUSIO Inc.提出集体诉讼,指控其针对Hurler综合症使用RGX-111基因疗法的误导性陈述进行证券诈骗。 A class action lawsuit has been filed against REGENXBIO Inc. alleging securities fraud over misleading statements about its gene therapy RGX-111, used for Hurler syndrome. 这起诉讼涉及2022年2月9日至2026年1月27日期间购买的股份。 该公司声称,该公司歪曲了治疗的安全和功效,没有在审判参与者中披露脑肿瘤。 The suit, covering shares bought between February 9, 2022, and January 27, 2026, claims the company misrepresented the therapy’s safety and efficacy, failing to disclose a brain tumor in a trial participant. 2026年1月28日, 林业发展局出于安全考虑, 对RGX-111和RGX-121实行临床搁置, 导致股价下跌17.9%。 On January 28, 2026, the FDA placed clinical holds on RGX-111 and RGX-121 due to safety concerns, triggering a 17.9% drop in the stock price. 遭受损失的投资者可在2026年4月14日前加入该案,无需预付参与费。 Investors who suffered losses may join the case by April 14, 2026, with no upfront fees for participating.